Technical Analysis for IBRX - ImmunityBio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 7.35 | 43.84% | 2.24 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| New 52 Week Closing High | Bullish | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| New 52 Week High | about 14 hours ago |
| 5x Volume Pace | about 15 hours ago |
| Possible Pocket Pivot | about 16 hours ago |
| Rose Above Upper Bollinger Band | about 16 hours ago |
| 3x Volume Pace | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.74 |
| 52 Week Low | 1.25 |
| Average Volume | 5,871,942 |
| 200-Day Moving Average | 3.46 |
| 50-Day Moving Average | 5.24 |
| 20-Day Moving Average | 5.52 |
| 10-Day Moving Average | 5.33 |
| Average True Range | 0.76 |
| RSI (14) | 65.99 |
| ADX | 17.18 |
| +DI | 40.02 |
| -DI | 12.33 |
| Chandelier Exit (Long, 3 ATRs) | 5.45 |
| Chandelier Exit (Short, 3 ATRs) | 6.88 |
| Upper Bollinger Bands | 6.70 |
| Lower Bollinger Band | 4.34 |
| Percent B (%b) | 1.28 |
| BandWidth | 42.77 |
| MACD Line | 0.12 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0734 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.58 | ||||
| Resistance 3 (R3) | 11.24 | 9.49 | 10.87 | ||
| Resistance 2 (R2) | 9.49 | 8.41 | 9.66 | 10.64 | |
| Resistance 1 (R1) | 8.42 | 7.75 | 8.95 | 8.76 | 10.40 |
| Pivot Point | 6.67 | 6.67 | 6.94 | 6.84 | 6.67 |
| Support 1 (S1) | 5.60 | 5.59 | 6.14 | 5.94 | 4.30 |
| Support 2 (S2) | 3.85 | 4.93 | 4.02 | 4.06 | |
| Support 3 (S3) | 2.78 | 3.85 | 3.83 | ||
| Support 4 (S4) | 3.12 |
